New Delhi, Oct 6: India has achieved a major milestone in vaccine development and cancer prevention as its first indigenously developed Human Papillomavirus (HPV) vaccine, Cervavac, has received prequalification from the World Health Organization (WHO).
Developed by the Serum Institute of India, Cervavac is a quadrivalent HPV vaccine designed to protect against four HPV types — 6, 11, 16 and 18. HPV infection is associated with cervical cancer as well as several other cancers and diseases.
The WHO prequalification is an important recognition of the vaccine's quality, safety and manufacturing standards. It also allows the vaccine to become eligible for procurement by United Nations agencies, opening the possibility of wider access in countries working to strengthen HPV vaccination programmes.
The achievement is significant for India's growing vaccine manufacturing sector. It also highlights the country's efforts to develop affordable and locally made vaccines that can address important public health needs.
Cervavac was developed in India with support from public-sector research institutions and international health organisations. The vaccine had earlier received approval for use in India.
HPV vaccination is considered an important tool in preventing cervical cancer, particularly when combined with regular screening and timely treatment. Expanding access to vaccination can help reduce the long-term burden of HPV-related diseases.
The WHO prequalification of Cervavac marks another step in India's journey from being a major vaccine manufacturer to becoming an increasingly important source of homegrown health solutions for the global community.
